EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials. Issue 3 (March 2019)

• Record Type: Journal Article
• Authors: Wong, Tien Yin; Cheung, Chui Ming Gemmy; Lai, Timothy Y. Y.; Chen, Shih-Jen; Lee, Won Ki; Yoon, Young Hee; Iida, Tomohiro; Tueckmantel, Claudia; Sowade, Olaf; Ogura, Yuichiro
• Is Part Of: Retina. Volume 39:Issue 3(2019)
• Publication Date: 2019-03
• Subjects: aflibercept -- age-related macular degeneration -- anti–vascular endothelial growth factor -- Asian patients; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000001986
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To assess the treatment effect of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration. Methods: We evaluated data from VIEW 1 and VIEW 2, comparing functional and morphologic outcomes at Week 96 between intravitreal aflibercept 2 mg monthly (2q4) or 2 mg bimonthly after 3 initial monthly doses (2q8) versus ranibizumab 0.5 mg monthly among Asian patients (n = 269) and between Asian and white patients (n = 2044). Results: In Asian patients, there were no significant differences between intravitreal aflibercept 2q4 and 2q8 compared with ranibizumab in mean gain in best-corrected visual acuity (10.23 and 8.35 vs. 8.51 letters). Reduction in central retinal thickness was greater for intravitreal aflibercept 2q4 (150.43 μ m, P = 0.0075) and 2q8 (148.15 μ m, P = 0.0126) than ranibizumab (119.46 μ m). The proportion of dry retinas was greater for intravitreal aflibercept 2q4 (65.7%, P < 0.01) than ranibizumab (41.7%). There were no differences in outcomes between Asian and white patients. Serious treatment-emergent ocular adverse events occurred in <8% of treated eyes, evenly distributed across subgroups. Conclusion: In Asian patients with neovascular age-related macular degeneration, functional and morphologic outcomes were largely similar between intravitreal aflibercept and ranibizumab groups, and to results seen in white patients. Abstract : Post hoc analyses of the Asian subpopulation of the VIEW trials demonstrated that visual and anatomic outcomes were similar in eyes treated with intravitreal aflibercept and ranibizumab, and were similar to outcomes seen in white patients.